# ANTI ALLERGIC OR ANTI INFLAMMATORY SUBSTITUTED HETERO ARALKYLAMINO ORTHO PHENOLS

## Abstract
Compounds of the general formula I

## Claims
1. A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt or solvate thereof, wherein R₁ is straight or branched C1 6 alkyl, halo, nitro, cyano, hydroxy, or COR₆ wherein R₆ is straight or branched C1 6 alkyl or aryl, R₂ is substituted to unsubstituted aryl, aralkyl or heteroaryl R₃ is hydrogen or straight or branched C1 6 alkyl R₄ is hydrogen, hydroxy, straight or branched C1 6 alkyl, halo, nitro, cyano, C1 6 alkoxy, halo C1 6 alkyl amino, carboxylic ester, carboxylic acid, COR₆,SR₆, SO₂R₆, NHCOR₆ or NHR₆ wherein R₆ is as defined above and R₅ is hydrogen, straight or branched C1 6 alkyl, substituted or unsubstituted benzyl or COR₆ wherein R₆ is as defined above and a pharmaceutically acceptable carrier.

## Description
The present invention relates to substituted aminophenols, to processes for preparing them, to pharmaceutical compositions containing them and their use in medicine. Japanese Published Patent Application Kokai No. 81 02976 discloses compounds of formula A It has been found that a class of aminophenol derivatives, certain of which are novel, are active as inhibitors of the enzyme 5 lipoxygenase, an important enzyme in the production of the spasmogenic peptide leukotrienes LTC₄, LTD₄, LTE₄ and inflammatory leukotriene LTB₄. These compounds are also active at inhibiting SRS A production According to the present invention there is provided a pharmaceutical composition comprising a compound of formula I As used herein the term aryl includes phenyl. Hetero aryl groups are typically 4 to 7 membered rings containing up to four heteroatoms selected from oxygen, sulphur and nitrogen. When R₁ is C Suitably R₂ is substituted or unsubstituted phenyl. As an heteroaryl group it may be, for exmaple, furan, thiophene, imidazole, isoxazole or pyridine and be substituted or unsubstituted. A suitable aralkyl group, which may also be substituted or unsubstituted, is benzyl. Suitable optional substituents for R₂ are one or more groups selected from straight or branched C Preferred substituents for R₂ are C Suitable carboxylic ester groups include CO₂R₆ where R₆ is as hereinbefore defined. R₂ substituents are typically Suitably R₃ is hydrogen, or methyl when C A suitable halo C Preferably R₄ is hydrogen. A suitable acyl COR₆ group for R₅ is COCH₃. Preferably R₅ is hydrogen. R₆ is typically methyl, ethyl, or phenyl. Within formula I there is a group of compounds in which R₁ is methyl, ethyl, Examples of compounds of formula I include 2 phenylmethylamino 4 chlorophenol, 2 phenylmethylamino 4 methylphenol, and salts and solvates thereof. Certain compounds of formula I are novel. Therefore further according to the present invention there is provided a compound of formula IA Suitable and preferred substituents are as described for formula I where appropriate. When compounds of formula IA form salts such as acid addition salts or solvates such as hydrates these also form part of this invention. The compounds of formula IA or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form. By pharmaceutically acceptable form is meant, inter alia, of a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels. A substantially pure form will generally contain at least 50 excluding normal pharmaceutical additives , preferably 75 , more preferably 90 and still more preferably 95 of the compound of formula I or its salt or solvate. One preferred pharmaceutically acceptable form is the crystalline form. Salt or solvates of compounds of formula IA which are not pharmaceutically acceptable, may be useful as intermediates to prepare pharmaceutically acceptable compounds of the invention. Suitable pharmaceutically acceptable salts of the invention are acid addition salts. Suitable acid addition salts of the compound of formula IA include pharmaceutically acceptable inorganic salts such as the sulphate, nitrate, phosphate, borate, hydrochloride and hydrobromide and pharmaceutically acceptable organic acid addition salts such as acetate, tartrate, maleate, citrate, succinate, benzoate, ascorbate, methanesulphate, α keto glutarate, α glycerophosphate, and glucose 1 phosphate. Preferably the acid addition salt is a hemisuccinate, hydrochloride, α ketoglutarate, α glycerophosphate or glucose 1 phosphate, in particular the hydrochloride salt. Examples of compounds of formula IA include 2 4 cyanophenyl methyl amino 4 methylphenol 2 4 methylphenyl methyl amino 4 methylphenol 2 4 methoxyphenyl methyl amino 4 methylphenol 2 4 chlorophenyl methyl amino 4 methylphenol 2 2 furyl methyl amino 4 methylphenol 2 3 trifluoromethylphenyl methyl amino 4 methyl phenol 2 4 fluorophenyl methyl amino 4 methyl phenol 2 3,4 dichlorophenyl methyl amino 4 methyl phenol 2 thien 2 yl methyl amino 4 methyl phenol 2 4 bromophenyl methyl amino 4 methyl phenol 2 3 fluorophenyl methyl amino 4 methyl phenol 2 phenylmethylamino 4 The present invention also provides a process for preparing compounds of formula I and IA wherein R₅ is hydrogen by hydrolysis of a compound of formula II The hydrolysis reaction is suitably carried out in the presence of an excess of base such as potassium or sodium hydroxide in an organic solvent e.g. methanol . The reaction is performed at an elevated temperature of from 30 C to 100 C under reflux. Compounds of formula II can be prepared by reaction of the compound of formula III The reaction is suitably carried out in an inert solvent such as a mixture of ethanol and water in the presence of a base. Suitable bases include sodium hydroxide and potassium hydroxide. The reaction is carried out at an elevated temperature of from 60 C 100 C under reflux. The compound of formula III can be prepared by reaction of a compound of formula V The reaction is suitably carried out at elevated temperatures of from 135 C to 320 C, preferably at 160 C, for a period of 2 3 hours. Compounds of formulae IV and V are either known compounds or can be prepared from known compounds by known methods. The present invention further provides a process for preparing compounds of formula I or IA wherein R₅ is hydrogen by reduction of a compound of formula VI Suitable reducing agents include hydrogen in the presence of a catalyst such as palladium, or hydride reducing agents. The particular hydride reagent employed can be selected in accordance with the nature of R₁, R₂, R₃ and R₄. Examples of such reagents are NaBH₃CN, B₂H₆ etc. The reaction will be carried out in an organic solvent such as ethanol and if necessary at a low pH for example at pH 1 2. Alternatively LiA1H₄ may suitably be used in ethereal solvents such as diethyl ether or tetrahydrofuran. Moderate temperature of from 0 C to 60 C, conveniently ambient temperature, will be employed. Compounds of formula VI can be prepared by reaction of a compound of formula V as hereinbefore defined, with a compound of formula VII The reaction is suitably carried out in an inert organic solvent such as toluene or an alcohol such as ethanol, at an elevated temperature of from 60 C to 150 C, preferably under reflux. When a water immiscible solvent such as toluene is used, water formed during the reaction is preferably removed using a trap. The present invention also provides a process for preparing a compound of formula I or IA wherein R₅ is hydrogen by reacting the compound of formula V with a compound of formula VII under reductive conditions. For example the reaction may be carried out in the presence of a hydride reducing agent such as NaBH₃CN at neutral pH in an organic solvent such as methanol. Moderate temperatures of for example 0 C 30 C suitably 25 C can be employed. The reaction can be carried out over an extended period of time, for example for 18 hours or more. If hydrogen in the presence of a catalyst such as platinum or nickel is used as the reducing agent, elevated temperatures of for example from 20 C to 100 C and or elevated pressures suitably of up to 10 atmospheres can be employed. The present invention further provides a process for preparing a compound of formula I or IA by reaction of a compound of formula VIII Suitable hydroxy protecting groups R₇ include benzyl optionally substituted with groups such as nitro or methoxy and SO₂ CH₃. The reaction is suitably carried out in an inert organic solvent such as N,N dimethylformamide in the presence of a base such as potassium hydroxide or sodium hydride. Elevated temperatures for example of from 25 C to 160 C are preferably employed. Alternatively the reaction is carried out in aqueous solution in the presence of a base such as sodium hydroxide at ambient temperature. Compounds of formula VII and VIII are either known compounds or can be produced from known compounds by conventional methods. The present invention additionally provides a process for preparing compounds of formula I and IA wherein R₃ is hydrogen and R₅ is hydrogen or straight or branched C Suitably R₈ is hydrogen, benzoyl or benzyl optionally substituted with groups such as nitro or methoxy. The reaction can be carried out in the presence of a hydride reducing agent. The hydride reducing agent will be selected to take into account any other reducible group present. Examples of hydride reducing agents which may be employed include BH₃ THF borane tetrahydrofuran , lithium aluminium hydride or borane dimethylsulphide. The reaction is suitably carried out in an inert solvent such as ether or tetrahydrofuran at a temperature of from 0 C to 80 C. Compounds of formula IX can be prepared from a compound of formula VIII as hereinbefore defined wherein R₇ is hydrogen and R₅ is hydrogen or straight or branched C Compounds of formula X , XI and XII are known compounds or can be prepared from known compounds by conventional methods. The present invention also provides a process for preparing a compound of formula I or IA wherein R₅ is COR₆ by reaction of a compound of formula XIII Suitable reaction conditions are those conventionally employed in acylation reactions. The present invention additionally provides a process for preparing a compound of formula I or IA wherein R₅ is hydrogen by reaction of a compound of formula XIV Suitable examples of Z include magnesium halide ion such as MgBr , and alkali metals such as lithium. The reaction is suitably carried out in an inert organic solvent such as dry ether or benzene under reflux. Compounds of formula XIV and XV are either known compounds or can be prepared from known compounds by known methods. The compound of formula I or IA prepared by any of the above described processes of the invention may be obtained where appropriate in the form of a salt and or solvate, preferably a pharmaceutically acceptable salt or solvate. Salts or solvates which are not pharmaceutically acceptable may be converted into salts or solvates which are pharmaceutically acceptable or into compounds per se. Compounds of formulae I or IA may be converted into other such compounds by suitable interconversion of substituents. The compounds of formula I and IA are indicated as active therapeutic agents by their inhibition of 5 lipoxygenase. Accordingly the present invention also provides a pharmaceutically acceptable compound of the formula I and IA , or a pharmaceutically acceptable salt or solvate thereof, for use in treatment of the human or animal body, particularly for the treatment or prophylaxis of allergic diseases, such as asthma, hayfever, rhinitis or allergic eczema, or for treatment of inflammatory conditions such as arthritis and psoriasis. The present invention also provides a pharmaceutical composition comprising a pharmaceutically acceptable compound of the formula I and IA , or a pharmaceutically acceptable salt or solvate thereof, in admixture or conjunction with a pharmaceutically acceptable carrier. Preferably, a pharmaceutical composition of the invention is in unit dosage form and in a form adapted for use in the medical or veterinarial fields. For example, such preparations may be in a pack form accompanied by written or printed instructions for use as an agent in the treatment of prophylaxis of any of the disorders mentioned above. The suitable dosage range for the compounds of the invention may vary from compound to compound and may depend on the condition to be treated. It will also depend, Compositions may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories. Compositions which are especially suitable for administration to the respiratory tract and for topical administration are discussed in more detail below. The compositions, for example those suitable for oral administration, may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone fillers, for example lactose, sugar, maize starch, calcium phosphate, sorbitol or glycine tabletting lubricants, for example magnesium stearate disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose or pharmaceutically acceptable setting agents such as sodium lauryl sulphate. Solid compositions may be obtained by conventional methods of blending, filling tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. When the composition is in the form of a tablet, powder, or lozenge, any carrier suitable for formulating solid pharmaceutical compositions may be used, examples being magnesium stearate, starch, glucose, lactose, sucrose, rice flour and chalk. Tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. The composition may also be in the form of an ingestible capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients. Compositions for oral administration as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid compositions may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats emulsifying agents, for example lecithin, sorbitan monooleate, or acacia aqueous or non aqueous vehicles, which include edible oils, for example almond oil, fractionated coconut oil, oily esters, for example esters of glycerine, or propylene glycol, or ethyl alcohol, glycerine, water or normal saline preservatives, for example methyl or propyl p hydroxybenzoate or sorbic acid and if desired conventional flavouring or colouring agents. The compounds of this invention may also be administered by a non oral route. In accordance with routine pharmaceutical procedure, the compositions may be formulated, for example for rectal administration as a suppository or for presentation in an injectable form in an aqueous or non aqueous solution, suspension or emulsion in a pharmaceutically acceptable liquid, e.g. sterile pyrogen free water or a parenterally acceptable oil or a mixture of liquids, which may contain bacteriostatic agents, anti oxidants or other preservatives, buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other pharmaceutically acceptable additives. Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid form or concentrate which can be used to prepare an injectable formulation. Compositions of this invention may also suitably be presented for administration to the respiratory tract as a snuff or an aerosol or solution for a nebulizer, or as a microfine powder for insufflation, alone or in combination with an inert carrier such as lactose. In such a case the particles of active compound suitably have diameters of less than 50 microns, preferably less than 10 microns. Where appropriate small amounts of other anti asthmatics and bronchodilators, for example sympathomimetic amines such as isoprenaline, isoetharine, salbutamol, phenylephrine and ephedrine xanthine derivatives such as theophylline and aminophylline and corticosteroids such as prednisolone and adrenal stimulants such as ACTH may be included. For topical administration, compositions may be presented as an ointment, cream, lotion, gel, gel stick, spray, aerosol, or skin paint. By way of example, in any of the preceding formulations a suitable dosage unit might contain 0.01 to 500 mgs of active ingredient, more suitably 1 to 500 mgs Within the above mentioned dosage ranges, no adverse toxicological effects are indicated with the compounds of the invention. The present invention also provides a method for treating allergic diseases or inflammatory conditions in human or non human animals which comprises administering to the sufferer an effective non toxic amount of a compound according to formula I or IA or a pharmaceutically acceptable salt or solvate thereof. Also included in the present invention is the use of a compound of formula I or IA , or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for treatment of the above disorders. Compounds of this invention, their preparation and their biological activity are illustrated in the following Examples and Pharmacological Data. The compounds set out in Tables I and II were prepared by methods analogous to those described in Examples 1 to 6. 2 Amino 4 methylphenol 6.5g, 53mmol and urea 4g,67mmol were heated together at 160 C for 2½ hours and cooled. The resulting solid was partitioned between 2Nag.hydrochloric acid and diethyl ether. The organic solution was dried MgSO₄ , concentrated Found C 64.60 H 4.60 N 9.30 . C₈H₇NO requires C 64.41 H 4.73 N 9.39 . 5 Methyl 2 3H benzoxazolinone 1g, 6.7mmol and benzylbromide 1.26g, 7.35mmol in EtOH 40ml were heated together under reflux in the presence of potassium hydroxide 0.42g, 7.5mmol in H₂O 4ml for 80 mins. The mixture was allowed to cool, the resulting solid was collected by filtration and recrystallized from EtOH to afford the title compound 1.42g, 89 as a white solid. mp 123 4 C. ν Found C 75.59 H 5.43 N 5.91 . C₁₅H₁₃NO₂ requires C 75.29 H 5.47 N 5.86. 3 Phenylmethyl 5 methyl 2 benzoxazolinone 5g, 21mmol and potassium hydroxide 7g. 0.126mol in MeOH 40ml were heated together under reflux for 1 hour. The solvent was removed Found C 67.13 H 6.47 N 5.60 . C₁₄H₁₆ClNO requires C 67.33 H 6.48 N 5.61 . 2 Amino 4 methylphenol 1.9g, 15.3mmol and 4 cyanobenzaldehyde 2g, 15.3mmol were heated together under reflux in toluene 2.5ml for 4 hours removing the water produced with a Dean and Stork trap. The solution was allowed to cool, the resulting solid collected by filtration, washed with toluene and recrystallised from Et₂O. The title compound 3.09g, 86 was obtained as a yellow solid m.p. 152 3 C. ν Found C 76.31 H 5.15 N 11.92 . C₁₅H₁₂N₂O requires C 76.25 H 5.12 N 11.86 . A suspension of 2 4 cyanobenzylidene amino 4 methylphenol 1.8g, 7.6mmol in EtOH 20ml at room temperature was acidified to pH 1 with ethanolic hydrogen chloride and treated portionwise with sodium cyanoborohydride 0.5g, 7.6mmol over 10 mins. The reaction mixture was maintained at pH 1 2 by the addition of ethanolic hydrogen chloride. After 1 hour the mixture was poured onto ice, neutralised with aqueous sodium bicarbonate solution and the resulting solid collected by filtration. Recrystallisation from Et₂O afforded the title compound 1.14g, 63 as a white solid mp 137 138 C. ν Found C 75.63 H 6.04 N 11.86 . C₁₅H₁₄N₂O requires C 75.60 H 5.92 N 11.76 . 2 Amino 4 methylphenol 4.93g, 40mmol and 4 methylbenzaldehyde 4.81g, 40mmol in methanol 50ml were stirred with sodium cyanoborohydride 2.51g, 40mmol at 25 C for 18 hours. The reaction mixture was poured into H₂O 250ml , extracted with CH₂Cl₂ 3 50 ml and the combined extracts dried MgSO₄ . Concentration ν Found C 68.36 H 7.04 N 5.45 Cl 13.48 . C₁₅H₁₈ClNO requires C 68.30 H 6.88 N 5.31 Cl 13.44 . This compound was prepared by methods analogous to those described in examples 4 6 and characterised as its hydrochloride salt. m.p. 186 7 C EtOH . Found C 68.14 H 6.84 N 5.30 Cl 13.22 . C₁₅H₁₈ClNO requires C 68.30 H 6.88 N 5.31 Cl 13.44 . 2 Benzoylamino 4 methylphenol 520mg, 2.3mmol , prepared according to the method of Seha Helv. Chim. Acta. 1980, 2 Benzoylamino 4 methylphenol This compound was prepared from 4 benzoyl 6 aminoresorcinol by methods analogous to those described in examples 4 6. m.p. 209 211 C. Found C 67.59 H 5.26 N 3.97 . C₂₀H₁₈ClNO₃ requires C 67.51 H 5.10 N 3.94 . A solution of 2 amino 4 methylphenol 12.32g, 0.1mol in 2N aq. NaOH 50ml was stirred with benzyl bromide 17.1g, 0.1mol at room temperature for 18 hours. The mixture was extracted with Et₂O 2 100ml , the combined extracts washed successively with 2N aq.NaOH solution 50ml and H₂O 50ml and dried MgSO₄ . Concentration The minor component from the chromatographic separation was taken up into Et₂O and treated with etherial hydrogen chloride to afford a white solid which was collected by filtration and recrystallised from EtOH. This compound was shown to be 2 phenylmethylamino 4 methylphenol hydrochloride 1.55g, 7 by comparison with a previously prepared sample. m.p. 181 2 C. Found C 67.14 H 6.56 N 5.32 Cl 14.22. C₁₄H₁₆ClNO requires C 67.33 H 6.48 N 5.61 Cl 14.20. 5 Lipoxygenase enzyme was prepared as a 10,000g supernatant from RBL 1 cells by the method of Jakschik Jakschik, B.A., F.F. Sun, L.M. Lee, and M.M. Steinhoff, 1980, Biochem. Biophys. Res. Comm.